RSS

Vifor Fresenius Medical Care Renal Pharma

The European Medicines Agency (EMA) has accepted the conditional marketing authorisation application for avacopan in the treatment of patients with anti-neutrophil cytoplasmic antibody associated vasculitis. more

News

Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Relypsa, have announced a partnership to commercialise Relypsa's investigational medicine for the treatment of hyperkalaemia more

News